Viewing Study NCT07100392


Ignite Creation Date: 2025-12-24 @ 3:56 PM
Ignite Modification Date: 2026-01-01 @ 11:42 PM
Study NCT ID: NCT07100392
Status: RECRUITING
Last Update Posted: 2025-08-17
First Post: 2025-07-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Sponsor: Fudan University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module